A Peptide Inhibitor of c-Jun N-Terminal Kinase for the Treatment of Endotoxin-Induced Uveitis
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
PURPOSE: To evaluate the effect of XG-102 (formerly D-JNKI1), a TAT-coupled dextrogyre peptide that selectively inhibits the c-Jun N-terminal kinase, in the treatment of endotoxin-induced uveitis (EIU). METHODS: EIU was induced in Lewis rats by LPS injection. XG-102 was administered at the time of LPS challenge. The ocular biodistribution of XG-102 was evaluated using immunodetection at 24 hours after either 20 microg/kg IV (IV) or 0.2 microg/injection intravitreous (IVT) administrations in healthy or uveitic eyes. The effect of XG-102 on EIU was evaluated using clinical scoring, infiltration cell quantification, inducible nitric oxide synthase (iNOS) expression and immunohistochemistry, and cytokines and chemokines kinetics at 6, 24, and 48 hours using multiplex analysis on ocular media. Control EIU eyes received vehicle injection IV or IVT. The effect of XG-102 on c-Jun phosphorylation in EIU was evaluated by Western blot in eye tissues. RESULTS: After IVT injection, XG-102 was internalized in epithelial cells from iris/ciliary body and retina and in glial and microglial cells in both healthy and uveitic eyes. After IV injection, XG-102 was concentrated primarily in inflammatory cells of uveitic eyes. Using both routes of administration, XG-102 significantly inhibited clinical signs of EIU, intraocular cell infiltration, and iNOS expression together with reduced phosphorylation of c-Jun. The anti-inflammatory effect of XG-102 was mediated by iNOS, IFN-gamma, IL-2, and IL-13. CONCLUSIONS: This is the first evidence that interfering with the JNK pathway can reduce intraocular inflammation. Local administration of XG-102, a clinically evaluated peptide, may have potential for treating uveitis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interfering with the p38 pathway by the use of the specific inhibitor XG-102 has been shown to reduce intraocular inflammation [ 187 ] in a dose-dependent manner [ 188 ] in a rat LPS-induced uveitis model”
From MAPK Pathways in Ocular Pathophysiology: Potential Therapeutic Drugs and Challenges (2023) · cites this paper as [187]
Citations
Cites
Multiplexed particle-based flow cytometric assays
Vignali, D. A. A. (2000) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00238-6 · Cited by 913
A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia
Borsello, T., Clarke, P. G. H., Hirt, L., Vercelli, A., Repici, M., Schorderet, D. F., Bogousslavsky, J., & Bonny, C. (2003) · Nature Medicine · doi:10.1038/nm911 · Cited by 658
Targeting JNK for therapeutic benefit: from junk to gold?
Manning, A. M., & Davis, R. J. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1132 · Cited by 585
Cell-Permeable Peptide Inhibitors of JNK
Bonny, C., Oberson, A., Negri, S., Sauser, C., & Schorderet, D. F. (2001) · Diabetes · doi:10.2337/diabetes.50.1.77 · Cited by 571
Swantek, J. L., Cobb, M. H., & Geppert, T. D. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.11.6274 · Cited by 491
Jun N-Terminal Kinase in Rheumatoid Arthritis
Han, Z., Boyle, D. L., Aupperle, K. R., Bennett, B., Manning, A. M., & Firestein, G. S. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35079-7 · Cited by 156
Wang, J., Ruel, J., Ladrech, S., Bonny, C., Water, T. R. V. D., & Puel, J. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.028936 · Cited by 153
Goureau, O., Bellot, J., Thillaye, B., Courtois, Y., & de Kozak, Y. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.12.6518 · Cited by 140
Hirt, L., Badaut, J., Thevenet, J., Granziera, C., Regli, L., Maurer, F., Bonny, C., & Bogousslavsky, J. (2004) · Stroke · doi:10.1161/01.str.0000131480.03994.b1 · Cited by 133
Eshraghi, A. A., Wang, J., Adil, E. A., He, J., Zine, A., Bublik, M., Bonny, C., Puel, J., Bałkany, T. J., & Water, T. R. V. D. (2006) · Hearing Research · doi:10.1016/j.heares.2006.09.008 · Cited by 120
Cited by
Cell-Penetrating Peptides: From Basic Research to Clinics
Guidotti, G., Brambilla, L., & Rossi, D. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.01.003 · Cited by 1,147
“In the context of pain and inflammation, Xigen SA moved into clinical development XG-102 (previously known as D-JNKI-1), a CPP inhibitor of JNK that was already shown to have potential for the treatment of intraocular inflammation in rat models of uveitis [33,111].”
BackgroundCell penetrating peptides: the potent multi-cargo intracellular carriers
Kardani, K., Milani, A., H. Shabani, S., & Bolhassani, A. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1676720 · Cited by 199
Role of the JNK Pathway in Human Diseases
Sabapathy, K. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-396456-4.00013-4 · Cited by 167
Girol, A. P., Mimura, K. K. O., Drewes, C. C., Bolonheis, S. M., Solito, E., Farsky, S. H. P., Gil, C. D., & Oliani, S. M. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202030 · Cited by 136
“Our in vivo analyses found that the inflammatory stimulus induced by LPS caused the release of chemical mediators (TNF-a, IL-1b, IL-6, and NO), increased expression of the proinflammatory enzyme COX-2, breakdown of the blood–ocular barrier, and intense influx of leukocytes in EIU 24h rats (9, 14, 21).”
BackgroundInhibitors of c-Jun N-Terminal Kinases: An Update
Koch, P., Gehringer, M., & Laufer, S. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501212r · Cited by 112
Anti-inflammatory effect of conditioned medium from human uterine cervical stem cells in uveitis
Bermúdez, M. A., Sendón-Lago, J., Seoane, S., Eiró, N., González, F., Saá, J., Vizoso, F. J., & Pérez-Fernández, R. (2016) · Experimental Eye Research · doi:10.1016/j.exer.2016.06.022 · Cited by 86
Peptide-based delivery of therapeutics in cancer treatment
Samec, T., Boulos, J., Gilmore, S. N., Hazelton, A., & Alexander-Bryant, A. A. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100248 · Cited by 94
Zhao, M., Bousquet, E., Valamanesh, F., Farman, N., Jeanny, J., Jaisser, F., & Béhar‐Cohen, F. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-7675 · Cited by 82
“EIU was induced in rats by a single footpad injection of 100 L sterile pyrogen-free saline containing 200 g lipopolysaccharide (LPS) from Salmonella typhimurium (Sigma-Aldrich) as previously described.(24) Intravitreous injections of 100 nM dex or TA were performed in the rat eyes at the time of LPS challenge.”
MethodSelf-citationMAPK Pathways in Ocular Pathophysiology: Potential Therapeutic Drugs and Challenges
Moustardas, P., Aberdam, D., & Lagali, N. (2023) · Cells · doi:10.3390/cells12040617 · Cited by 63
“Interfering with the p38 pathway by the use of the specific inhibitor XG-102 has been shown to reduce intraocular inflammation [187] in a dose-dependent manner [188] in a rat LPS-induced uveitis model and also in patients with post-operative inflammation after anterior and posterior segment combined surgery, glaucoma…”
MethodJing, C., Sun, Z., Xie, X., Zhang, X., Wu, S., Guo, K., & Bi, H. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109381 · Cited by 61
Bioelectricity for Drug Delivery: The Promise of Cationic Therapeutics
Young, C. C., Vedadghavami, A., & Bajpayee, A. G. (2020) · Bioelectricity · doi:10.1089/bioe.2020.0012 · Cited by 60
Chiquet, C., Aptel, F., Creuzot-Garcher, C., Berrod, J.-P., Kodjikian, L., Massin, P., Deloche, C., Perino, J., Kirwan, B.-A., de Brouwer, S., et al. (2017) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2016.10.012 · Cited by 52
Self-citationThe JNK Inhibitor XG-102 Protects against TNBS-Induced Colitis
Reinecke, K., Eminel, S., Dierck, F., Roessner, W., Kersting, S., Chromik, A. M., Gavrilova, O., Laukevicience, A., Leuschner, I., Waetzig, V., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030985 · Cited by 47
“matic hearing loss [36] and uveitis [37].”
BackgroundRole of C-Jun N-terminal Kinase in Hepatocellular Carcinoma Development
Wang, J., & Tai, G. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0446-5 · Cited by 45
Bousquet, E., Zhao, M., Ly, A., Leroux les Jardins, G., Goldenberg, B., Naud, M.-C., Jonet, L., Besson-Lescure, B., Jaisser, F., Farman, N., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049036 · Cited by 40
Self-citationBeydoun, T., Deloche, C., Perino, J., Kirwan, B.-A., Combette, J.-M., & Behar-Cohen, F. (2015) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2013.0247 · Cited by 39
“…and that local administration of XG-102 significantly reduced the ocular inflammation score, inflammatory cell infiltration, and inducible nitric oxide synthase expression in rat eyes, 31 suggesting that XG-102 could have potential efficacy in the treatment of intraocular inflammation in humans.”
Self-citationFruchon, S., Caminade, A., Abadie, C., Davignon, J., Combette, J., Turrin, C., & Poupot, R. (2013) · Molecules · doi:10.3390/molecules18089305 · Cited by 39
“This model is considered as a clinically relevant model for human anterior uveitis [15–17].”
BackgroundSelf-citationDeloche, C., Lopez‐Lazaro, L., Mouz, S., Perino, J., Abadie, C., & Combette, J. (2014) · Pharmacology Research & Perspectives · doi:10.1002/prp2.20 · Cited by 37
Self-citationProtective effects of the galectin-1 protein on in vivo and in vitro models of ocular inflammation.
Zanon, C. D. F., Sonehara, N. M., Girol, A. P., Gil, C. D., & Oliani, S. M. (2015) · PubMed Central · Cited by 36
Bioportides: Bioactive cell‐penetrating peptides that modulate cellular dynamics
Lukanowska, M., Howl, J., & Jones, S. (2013) · Biotechnology Journal · doi:10.1002/biot.201200335 · Cited by 34
El Zaoui, I., Touchard, E., Berdugo, M., Abadie, C., Kowalczuk, L., Deloche, C., Zhao, M., Naud, M.-C., Combette, J.-M., & Behar-Cohen, F. (2015) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2014.0019 · Cited by 31
“12,18,19 In this study, we confirmed that XG-102 exerts anti-inflammatory effects on EIU using IV and IVT.”
InfluentialSelf-citationNovel DOCK2-selective inhibitory peptide that suppresses B-cell line migration
Sakamoto, K., Adachi, Y., Komoike, Y., Kamada, Y., Koyama, R., Fukuda, Y., Kadotani, A., Asami, T., & Sakamoto, J. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.12.170 · Cited by 29
Yang, X., Jin, H., Liu, K., Gu, Q., & Xu, X. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029155 · Cited by 29
Kersting, S., Behrendt, Kersting, Reinecke, Hilgert, Stricker, Herdegen, Janot-Matuschek, M. S., Uhl, & Chromik (2013) · Journal of Inflammation Research · doi:10.2147/jir.s40092 · Cited by 30
Zhu, S., Xu, X., Wang, L., Su, L., Gu, Q., Wei, F., & Liu, K. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1121-z · Cited by 21
“In this regard, small peptides derived from key active parts of certain functional proteins display promising potential to target ocular disorders [6, 11, 12].”
Peptide cargo administration: current state and applications
Rohira, H., Arora, A., Kaur, P., & Chugh, A. (2023) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-023-12512-5 · Cited by 21
“In preclinical studies, XG-102 demonstrated anti-inflammatory potential to treat experimental uveitis in murine model after being administered through different routes (intravenous, intravitreal and subconjunctival) (Touchard et al. 2010; Zaoui et al. 2015).”
BackgroundDual Kinase Inhibition Affords Extended in vitro Neuroprotection in Amyloid-β Toxicity
Gourmaud, S., Mouton‐Liger, F., Abadie, C., MEURS, E. F., Paquet, C., & Hugon, J. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160509 · Cited by 17
Self-citationPortillo, J. C., Yu, J., Hansen, S., Kern, T. S., Subauste, M. C., & Subauste, C. S. (2021) · The FASEB Journal · doi:10.1096/fj.201903203rr · Cited by 15
Kyei, S., Koffuor, G. A., Ramkissoon, P., Ameyaw, E. O., & Asiamah, E. A. (2016) · International Journal of Ophthalmology · doi:10.18240/ijo.2016.04.08 · Cited by 14
Jiang, R., & Wang, X. (2022) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557522666220228150127 · Cited by 13
Wang, X., Wang, L., Lin, F.-L., Li, S.-S., Lin, T.-X., & Jiang, R. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/5526053 · Cited by 12
“A phase III clinical study was completed in 2016, confirming its ability to reduce intraocular inflammation and pain in patients undergoing cataract surgery [41, 42].”
BackgroundRelja, B., Weber, R., Maraslioglu, M., Wagner, N., Borsello, T., Jobin, C., Marzi, İ., & Lehnert, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137875 · Cited by 11
Benakis, C., Vaslin, A., Pasquali, C., & Hirt, L. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-76 · Cited by 12
“Others showed that D-JNKI1 significantly prevented liver injury after hemorrhage and resuscitation by inhibiting cytokine production [13], which is also true in a model of uveitis [14].”
BackgroundEspírito‐Santo, S., Mendonça, H. R., Menezes, G. D., Goulart, V. G., Gomes, A. L. T., Marra, C., Faria‐Melibeu, A. D. C., Serfaty, C. A., Sholl‐Franco, A., & Campello‐Costa, P. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.10.034 · Cited by 11
Potentiel des liposomes pour l’injection intravitréenne de molécules thérapeutiques
Bochot, A., Lajavardi, L., Camelo, S., Bourges, J., Béhar‐Cohen, F., de Kozak, Y., & Fattal, E. (2011) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2010.11.002 · Cited by 6
Vasorelaxing cell permeant phosphopeptide mimetics for subarachnoid hemorrhage
Morone, P. J., Yan, W., Adcock, J. M., Komalavilas, P., Mocco, J., Thompson, R. C., Brophy, C. M., & Cheung‐Flynn, J. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174038 · Cited by 5
Moving forward in uveitis therapy: preclinical to phase II clinical trial drug development
Méndez, R. S., Yilmaz, T., & Cordero‐Coma, M. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1128893 · Cited by 7
IV.E. Principles and Practice of Intravitreal Application of Drugs
Lin, P., Menda, S. A., & de Juan, E. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1086-1_29 · Cited by 6
Clinical Trials and Commercialization Using CPPs
Langel, Ü. (2019) · Springer eBooks · doi:10.1007/978-981-13-8747-0_11
Vedadghavami, A. (2022) · Digital Repository Service (Northeastern University) · doi:10.17760/d20449631
Oba, M. (2022) · Wiley eBooks · doi:10.1002/9783527835997.ch20
Clinical Trials and Commercialization Using CPPs
Langel, Ü. (2023) · Springer eBooks · doi:10.1007/978-3-031-38731-9_15
Cell penetrating and interfering peptides as new cancer therapy
Zhang, X. (2017) · theses.fr (ABES) · doi:10.70675/b2053021ze747z4f1azacb7z8a87a14ec9e3
BindingDB Entry 50045381: Inhibitors of c-Jun N-terminal kinases: an update.
BindingDB (2016) · UC San Diego · doi:10.7270/q2jh3nvz
Metadata
- Authors
- Touchard, E., Omri, S., Naud, M.-C., Berdugo, M., Deloche, C., Abadie, C., Jonet, L., Jeanny, J.-C., Crisanti, P., de Kozak, Y., Combette, J.-M., & Behar-Cohen, F.
- Affiliations
- Inserm (FR)
- RibOvax Biotechnologies S.A., Geneva, Switzerland; and
- From the INSERM, U872 Physiopathology of Ocular Diseases/Therapeutic Innovations, Paris, France; 2Centre de Recherche des Cordeliers, Université Pierre et Marie Curie—Paris6, UMR S 872, Paris, France; 3Université Paris Descartes, UMR S 872, Paris, France;
- Corresponding author
- Touchard, Elodie
- Omri, Samy
- Naud, Marie-Christine
- Berdugo, Marianne
- Deloche, Catherine
- Abadie, Claire
- Jonet, Laurent
- Jeanny, Jean-Claude
- Crisanti, Patricia
- Combette, Jean-Marc
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2010-09-01
- Volume
- 51
- Issue
- 9
- Pages
- 4683
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W2069483338
- Cited by
- 43
- References
- 30
- Citations by year
- 2023: 3 · 2022: 4 · 2021: 3 · 2020: 1 · 2019: 3 · 2017: 3 · 2016: 6 · 2015: 3 · 2014: 5 · 2013: 4 · 2012: 4
- FWCI
- 4.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Investigative Ophthalmology & Visual Science (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- endotoxin-induced uveitis, intravitreal administration, inducible nitric oxide synthase, c-Jun phosphorylation, intraocular inflammation, cytokines and chemokines, interferon-gamma, interleukin-2, IL-13, lipopolysaccharide, uveitis treatment
- MeSH terms
- Animals, Disease Models, Animal, Drug Combinations, Female, Injections, Intravenous, Lipopolysaccharides, Oils, Peptides, Phenols, Rats, Inbred Lew, Tissue Distribution, Uveitis, Vitreous Body, Signal Transduction, Down-Regulation, Cytokines, Chemokines, Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating), JNK Mitogen-Activated Protein Kinases, Rats, Nitric Oxide Synthase Type II, Injections, Intraocular
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.